Gyre Therapeutics (GYRE) Free Cash Flow (2010 - 2026)

Gyre Therapeutics (GYRE) has reported Free Cash Flow for 17 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow rose 1303.98% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $3.1 million (up 134.91% YoY), while the FY2025 annual figure was -$180000.0, up 96.98% from the prior year.
• Free Cash Flow improved to $3.0 million in Q1 2026 per GYRE's latest filing, from -$5.7 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $42.3 million in Q4 2022 and bottomed at -$12.3 million in Q2 2022.
• Historically, Free Cash Flow has averaged $1.5 million across 5 years, with a median of $1.0 million in 2023.
• Annual changes were most pronounced in 2024 — Free Cash Flow plunged 437.99% — and 2026, when it jumped 1303.98%.
• Gyre Therapeutics' Free Cash Flow stood at $42.3 million in 2022, then plunged by 97.55% to $1.0 million in 2023, then sank by 359.94% to -$2.7 million in 2024, then plunged by 112.92% to -$5.7 million in 2025, then surged by 152.7% to $3.0 million in 2026.
• Business Quant data shows GYRE's Free Cash Flow at $3.0 million in Q1 2026, -$5.7 million in Q4 2025, and $3.9 million in Q3 2025.